188 related articles for article (PubMed ID: 36802324)
1. Etranacogene Dezaparvovec: First Approval.
Heo YA
Drugs; 2023 Mar; 83(4):347-352. PubMed ID: 36802324
[TBL] [Abstract][Full Text] [Related]
2. Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency).
Sekayan T; Simmons DH; von Drygalski A
Expert Opin Biol Ther; 2023; 23(12):1173-1184. PubMed ID: 37962325
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
[TBL] [Abstract][Full Text] [Related]
4. Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B.
Klamroth R; Bonner A; Gomez K; Monahan PE; Szafranski K; Zhang X; Walsh S; Wang D; Yan S
Haemophilia; 2024 Jan; 30(1):75-86. PubMed ID: 37902714
[TBL] [Abstract][Full Text] [Related]
5. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
Pipe SW; Leebeek FWG; Recht M; Key NS; Castaman G; Miesbach W; Lattimore S; Peerlinck K; Van der Valk P; Coppens M; Kampmann P; Meijer K; O'Connell N; Pasi KJ; Hart DP; Kazmi R; Astermark J; Hermans CRJR; Klamroth R; Lemons R; Visweshwar N; von Drygalski A; Young G; Crary SE; Escobar M; Gomez E; Kruse-Jarres R; Quon DV; Symington E; Wang M; Wheeler AP; Gut R; Liu YP; Dolmetsch RE; Cooper DL; Li Y; Goldstein B; Monahan PE
N Engl J Med; 2023 Feb; 388(8):706-718. PubMed ID: 36812434
[TBL] [Abstract][Full Text] [Related]
6. Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
Castaman G; Coppens M; Pipe SW
Expert Rev Hematol; 2023; 16(12):919-932. PubMed ID: 37882214
[TBL] [Abstract][Full Text] [Related]
7. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.
von Drygalski A; Gomez E; Giermasz A; Castaman G; Key NS; Lattimore SU; Leebeek FWG; Miesbach WA; Recht M; Gut R; Dolmetsch R; Monahan PE; Le Quellec S; Pipe SW
Blood Adv; 2023 Oct; 7(19):5671-5679. PubMed ID: 36490302
[TBL] [Abstract][Full Text] [Related]
8. Etranacogene dezaparvovec for hemophilia B gene therapy.
Thornburg CD
Ther Adv Rare Dis; 2021; 2():26330040211058896. PubMed ID: 37181105
[TBL] [Abstract][Full Text] [Related]
9. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.
Von Drygalski A; Giermasz A; Castaman G; Key NS; Lattimore S; Leebeek FWG; Miesbach W; Recht M; Long A; Gut R; Sawyer EK; Pipe SW
Blood Adv; 2019 Nov; 3(21):3241-3247. PubMed ID: 31698454
[TBL] [Abstract][Full Text] [Related]
10. Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States.
Yan S; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Wilson M
J Med Econ; 2024; 27(1):758-765. PubMed ID: 38708771
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany.
Meier N; Fuchs H; Galactionova K; Hermans C; Pletscher M; Schwenkglenks M
Pharmacoecon Open; 2024 May; 8(3):373-387. PubMed ID: 38520664
[TBL] [Abstract][Full Text] [Related]
12. Hemophilia Gene Therapy: The End of the Beginning?
De Wolf D; Singh K; Chuah MK; VandenDriessche T
Hum Gene Ther; 2023 Sep; 34(17-18):782-792. PubMed ID: 37672530
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for hemophilia.
Nathwani AC
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):569-578. PubMed ID: 36485127
[TBL] [Abstract][Full Text] [Related]
14. Hemgenix - A gene therapy for hemophilia B.
Med Lett Drugs Ther; 2023 Jan; 65(1668):9-10. PubMed ID: 36651790
[No Abstract] [Full Text] [Related]
15. Fidanacogene Elaparvovec: First Approval.
Dhillon S
Drugs; 2024 Apr; 84(4):479-486. PubMed ID: 38472707
[TBL] [Abstract][Full Text] [Related]
16. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
17. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
Hermans C; Marino R; Lambert C; Mangles S; Sommerer P; Rives V; Maro G; Malcangi G
Adv Ther; 2020 Jun; 37(6):2988-2998. PubMed ID: 32333327
[TBL] [Abstract][Full Text] [Related]
18. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.
Kavakli K; Smith L; Kuliczkowski K; Korth-Bradley J; You CW; Fuiman J; Zupančić-Šalek S; Abdul Karim F; Rendo P
Haemophilia; 2016 May; 22(3):381-8. PubMed ID: 26823276
[TBL] [Abstract][Full Text] [Related]
19. [Prophylaxis in haemophilia B. Prevention of bleeds and FIX consumption].
Siegmund B; Richter H; Pollmann H
Hamostaseologie; 2010 Nov; 30 Suppl 1():S35-8. PubMed ID: 21042666
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the treatment of haemophilia B: laboratory and clinical perspectives.
Aledort LM
Haemophilia; 2010 Jul; 16 Suppl 6():1-2. PubMed ID: 20561350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
